Stay updated with breaking news from Nasdaq Elym. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Rating) saw a significant decline in short interest in May. As of May 15th, there was short interest totalling 18,800 shares, a decline of 5.5% from the April 30th total of 19,900 shares. Based on an average trading volume of 14,000 shares, the short-interest ratio is presently 1.3 days. […]
Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Rating) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 19,900 shares, an increase of 33.6% from the April 15th total of 14,900 shares. Based on an average daily volume of 16,700 shares, the […]
Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Rating) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 19,900 shares, a growth of 33.6% from the April 15th total of 14,900 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average […]
Presented initial preclinical data from ETX-123, Eliem's lead Kv7 program candidate, demonstrating a promising profile and confirming the proposed...
Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Rating) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 24,600 shares, an increase of 25.5% from the March 15th total of 19,600 shares. Currently, 0.1% of the shares of the stock are sold short. Based on […]